Picture loading failed.

Anti-CD3E therapeutic antibody (Pre-made Muromonab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants. It is a monoclonal antibody targeted at the CD3 receptor, a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-360-1mg 1mg 3090
GMP-Bios-ab-360-10mg 10mg 21890
GMP-Bios-ab-360-100mg 100mg 148000
GMP-Bios-ab-360-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD3E therapeutic antibody (Pre-made Muromonab biosimilar,Whole mAb)
INN Name Muromonab
TargetCD3E
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2a
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusDiscontinued
100% SI Structure1sy6:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed1988
Year Recommended1989
CompaniesCancer Research UK;Ortho-McNeil;XOMA
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDiabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis
Development Techna